Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Lap and Specialty Sponges, OR Towels

CHARLOTTE, N.C.--(BUSINESS WIRE)-- The Premier healthcare alliance today announced that new agreements for lap and specialty sponges, and OR towels have been awarded to AllCare Inc. of Bartlett, Ill.; AMD-Ritmed Inc. of Tonawanda, N.Y.; Cardinal Health of McGaw Park, Ill.; and Medline Industries Inc. of Mundelein, Ill.

Effective June 1, 2011, the agreements are available to acute care and continuum of care members of Premier.

About the Premier healthcare alliance, Malcolm Baldrige National Quality Award recipient

Premier is a performance improvement alliance of more than 2,500 U.S. hospitals and 75,000-plus other healthcare sites using the power of collaboration to lead the transformation to high quality, cost-effective care. Owned by hospitals, health systems and other providers, Premier maintains the nation's most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier has worked with the Centers for Medicare & Medicaid Services and the United Kingdom's National Health Service North West to improve hospital performance. Headquartered in Charlotte, N.C., Premier also has an office in Washington. http://www.premierinc.com. Stay connected with Premier on Facebook, Twitter and YouTube.



CONTACT:

Premier healthcare alliance
Tanya Bowman, 704-816-5231

KEYWORDS:   United States  North America  California  District of Columbia  Illinois  New York  North Carolina  Pennsylvania

INDUSTRY KEYWORDS:   Technology  Data Management  Health  Hospitals  Medical Devices  Pharmaceutical  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.